

Index

A

Access forums, 161
Access Working Group, 155, 158
Acute toxicity, 62
Adaptive designs, 109
Adherence counseling, 165
Adherence, 100, 101, 105, 107–109, 111, 156, 158, 165
Adolescents, 106, 108
Advocacy, 129
Alliance for Microbicide Development, 158, 159
Animal models, 124
ARV, 1, 9, 14, 15
AVAC, 162, 166

B

Bill and Melinda Gates Foundation, 161, 167
Branding and marketing, 169
Buehler, 66
BufferGel[®], 29, 33, 80, 104, 106, 122, 124, 156

C

CAPRISA 004 trial, 100, 102, 104, 105, 156, 161, 168
Carcinogenicity, 65, 66, 72
Carraguard[®], 29, 33, 80, 90, 100, 103, 106, 122, 156
Cellulose sulfate, 100, 103
CHARM program, 128
Clinical development, 125
Coitally dependent dosage forms, 32
Coitally independent dosage forms, 42
Community engagement, 166, 169
Cytotoxicity, 60, 67, 70

D

Dapivirine, 100, 105, 157
Demand forecasting, 159, 170
Dose volume, 63
Drug-device combinations, 70

E

Effectiveness, 98–102, 104–106, 108–110
Efficacy, 98–101, 103, 109, 110
Electrospun fibers, 45
EMA, 164
Ethics and regulatory bodies, 164
Explants, 89, 90

F

FACTS 001, 102, 105
Family planning centers, 168
FDA, 164
Female condom, 158, 159, 161, 168, 170
Female genital tract, 83, 88
FEM-PrEP trial, 101
FHI 360, 167
Films, 30, 31, 36–39
First generation microbicides, 156
Formulation development, 121
Founder virus, 120, 123

G

Gel applicators, 35
Gels, 29–35, 39, 41
Gender issues, 165
Genotoxicity, 64, 70, 72
Global Campaign for Microbicides, 158
Good Manufacturing Practice, 170

H

HIV, 80–91, 138–144, 146–148, 150
 HIV-1, 1–9, 11, 12, 14
 HIV-1 transmission, 118–125
 HIV services delivery facilities, 168
 HIVNET-008, 125
 HPTN 035 trial, 104
 Hyperosmolar products, 121
 Hypersensitivity reaction, 66

I

Immunity, 81, 84, 86
 Inflammatory response, 68
 International Partnership for Microbicides, 154,
 156–158, 160, 161, 164

L

Local lymph node assay, 66

M

Macaques, 69, 71
 Market research, 169
 Maximization test, 66
 MDP 301 trial, 104
 Metabolism, 61
 Metabolite characterization, 61
 Microbicide Development Strategy, 159
 Microbicide, 1, 2, 5, 7–14, 28–35, 37–47, 80,
 81, 83–89, 91, 101–111, 138, 139, 142–
 150
 MTN-007, 125, 126, 129
 MTN-017, 129
 Mucosal HIV acquisition, 1
 Multi-drug combination, 71
 Multipurpose products, 109

N

Nonhuman primate, 99, 122
 Nonoxynol-9, 103, 155
 Nonspecific microbicides, 29, 33, 36

O

Occluded patch, 66
 Operations and implementation research, 162,
 167, 168

P

PATH, 154, 170, 171
 pH, 58, 60
 Pharmacokinetics, 58, 61, 63, 71, 72, 87
 Pipeline, 120
 Policy development, 165, 167
 Polymers, 103
 Population Council, 161, 167
 Preclinical formulations, 57
 Preclinical methods, 1
 Preclinical testing, 123, 124
 Pregnancy, 102
 PRO2000[®], 99, 103, 104, 156, 161, 162
 Process flow for components of microbicide
 introduction, 163
 Product Development Partnership (PDP)
 Access Group, 160

Q

Quick working group, 158, 164

R

Rabbit vaginal irritation study, 68, 70
 Receptive anal intercourse, 120, 128, 129
 Rectal microbicides
 acceptability, 117, 118, 125, 128
 formulation, 121
 preclinical, 121–125
 Regulatory pathways, 163
 Regulatory strategy, 144, 150
 Repeat dose toxicology, 62
 Reproductive toxicology, 64
 Resistance, 108, 110
 RMP-01, 125, 126
 RMP-02/MTN-006, 125, 126

S

Safety pharmacology, 58, 60, 72
 SAVVY[®], 103
 SCID mouse, 124
 Secondary pharmacology, 58, 60
 Segment I, 64, 65, 71
 Segment II, 64, 65
 Segment III, 64
 Sensitization, 66, 67, 70
 Sexually transmitted infections, 60, 67
 SILCS diaphragm, 45–47

Silicone, 43, 157
Social and behavioral science, 162, 165, 169
South African medicines control council
(SA MCC), 164
Specific microbicide, 29
Sperm, 60
Superiority designs, 109
Surfactants, 103
Susceptibility to infection, 67, 69, 73
Systemic absorption, 58, 60, 61, 63, 64
Systemic toxicity, 61, 63

T

Tablets, 30, 31, 38–43
Tenofovir, 100, 102, 104–108, 110, 156, 157,
161, 162, 164, 168, 170
Transgenic mice, 65
Thermoplastic rings, 44
Toxicokinetics, 58, 61, 63

U

USAID, 162, 167
User-friendly instructions, 170

V

Vaginal drug delivery, 31, 32, 45
Vaginal microflora, 60, 68
Vaginal rings, 31, 42–43, 45, 157
VOICE trial, 102, 104–106, 156

W

WHO prequalification process, 164, 165
Woman-initiated, 169
World Health Organization, 155, 160, 161